This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the manufacturer of idelalisib has informed us that they will not provide an evidence submission for this appraisal. NICE will therefore suspend this appraisal and we will provide further updates when they are available.
 
Status Suspended
Process STA pre-2018
ID number 817

Project Team

Project lead Stephanie Yates

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Consultees

Companies sponsors Gilead Sciences
Others Department of Health
  NHS England
  NHS Bassetlaw CCG
  NHS Fylde & Wyre CCG
  Welsh Government
Patient carer groups None
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Janssen
Evidence review group Southampton Health Technology Assessments Centre
General commentators Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
19 October 2015 Draft scope documents
15 October 2015 Invitation to participate
05 October 2015 Suspended. This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the manufacturer of idelalisib has informed us that they will not provide an evidence submission for this appraisal. NICE will therefore suspend this appraisal and we will provide further updates when they are available.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance